Aziz Kabeer 4
4 · AN2 Therapeutics, Inc. · Filed Mar 23, 2026
Research Summary
AI-generated summary of this filing
AN2 Therapeutics Director Aziz Kabeer Receives Repriced Options
What Happened
Aziz Kabeer, a director of AN2 Therapeutics (ANTX), had repriced option awards granted on March 19, 2026 covering a total of 44,466 underlying shares (20,724 and 23,742). The Form 4 also reports simultaneous dispositions of the same derivative amounts to the issuer. The repriced options carry an exercise price of $3.91 per share and are fully vested. The board approved the repricing on March 19, 2026.
Key Details
- Transaction date: March 19, 2026; Form 4 filed March 23, 2026 (filed within the required reporting window).
- Reported items: Two grants (code A) for 20,724 and 23,742 derivative shares and matching dispositions to the issuer (code D) for the same amounts.
- Exercise price after repricing: $3.91 per share (footnote F1).
- Option status: fully vested (footnote F2).
- Repricing approved by board on March 19, 2026; other terms unchanged except as described (footnote F3).
- Shares owned after the reported transactions: not specified in the filing.
- Transaction codes: A = award/grant of a derivative security; D = disposition to the issuer. The filing does not show a cash purchase or an open-market sale.
Context
These entries reflect a corporate compensation/option repricing event rather than an open-market buy or sale by the director. The filing does not show an exercise resulting in market sales of shares (no cashless exercise or sale to market recorded). Footnote 1 also notes a “Premium End Date” (Sept 19, 2027, change in control, or death/disability) and a provision that the exercise price could revert to the original price under certain conditions. This type of repricing is typically an administrative/compensation action and should not be read as a simple buy or sell signal.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1][F3][F2]2026-03-19+20,724→ 20,724 totalExercise: $3.91Exp: 2032-05-11→ Common Stock (20,724 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F3][F2]2026-03-19−20,724→ 0 totalExercise: $17.28Exp: 2032-05-11→ Common Stock (20,724 underlying) - Award
Stock Option (right to buy)
[F1][F3][F2]2026-03-19+23,742→ 23,742 totalExercise: $3.91Exp: 2033-06-06→ Common Stock (23,742 underlying) - Disposition to Issuer
Stock Option (right to buy)
[F3][F2]2026-03-19−23,742→ 0 totalExercise: $5.91Exp: 2033-06-06→ Common Stock (23,742 underlying)
Footnotes (3)
- [F1]The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
- [F2]The option is fully vested.
- [F3]On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.